查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553690

藥物雜質合成和分離服務的市場規模、佔有率和趨勢分析報告：按服務、按雜質類型、按技術、按應用、按最終用途、按地區和細分趨勢：2024-2030

Pharmaceutical Impurity Synthesis And Isolation Services Market Size, Share & Trends Analysis Report By Services, By Impurity Type, By Technique, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

藥物雜質合成和分離服務市場的成長和趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球醫藥雜質合成與分離服務市場規模預計將達到19.4億美元，預測期內複合年成長率為8.03%。

藥物雜質檢測、定量和分析控制策略對於最佳化藥品成品和原料藥的安全性、純度和品管至關重要。藥品中的雜質可能來自多種來源，包括試劑、起始原料及其污染物、催化劑、中間體、溶劑、賦形劑及其污染物、分解產物。

藥物配方日益複雜也促進了市場成長。隨著生技藥品、複雜學名藥和新型藥物輸送系統的不斷發展，雜質的性質變得更加多樣化且難以識別。這種複雜性需要先進的分析技術和專家服務來進行準確的雜質分析。公司正在尋求專業服務來滿足這些需求，從而推動對雜質合成和分離服務的需求。因此，上述因素正在促進市場成長。

此外，分析技術的持續進步進一步推動了對雜質合成和分離服務的需求。高解析度質譜和先進層析法技術等更複雜方法的發展使得雜質的精確檢測和表徵成為可能。採用並整合這些最尖端科技的服務供應商可以輕鬆滿足製藥業不斷成長的需求，進一步推動市場成長。

製藥業合作研究和外包的成長趨勢在市場動態中發揮重要作用。為了專注於核心競爭力並降低營運成本，製藥公司擴大委託給專業服務供應商。這種外包趨勢為服務供應商擴大服務範圍並滿足世界各地客戶的需求創造了機會。因此，上述因素正在推動市場成長。

藥物雜質合成和分離服務市場報告亮點

  • 從服務業來看，2023年，分離服務業佔據市場主導地位，佔有率為39.41%。雜質分離是確保藥品安全性和有效性的基本方面。監管機構需要全面的雜質譜，並且需要將這些物質從藥品中有效分離。
  • 根據雜質類型，無機雜質細分市場將在 2023 年佔據主導地位。技術進步在無機雜質領域的主導地位中發揮著重要作用。感應耦合電漿質譜 (ICP-MS) 和原子吸收光譜 (AAS) 等分析技術的創新極大地提高了高靈敏度和高精度檢測和定量無機雜質的能力。
  • 按技術分類，層析法市場在 2023 年佔據最大的收益佔有率。藥物配方日益複雜，推動了對先進層析法技術的需求。現代藥物，包括生技藥品、胜肽和複雜的學名藥，通常含有複雜的混合物，需要適當的分離方法。
  • 按應用分類，商業製造領域在 2023 年佔據最大收益佔有率。全球藥品市場的成長和全球藥品生產設施的擴張正在推動該領域的成長。隨著製藥公司提高產能並進入新市場，對可靠的雜質分析服務的需求顯著增加。
  • 根據最終用途，生物技術和製藥公司部門在 2023 年佔據最大的收益佔有率。生物技術和製藥公司對研發（R＆D）的大量投資正在促進該領域的成長。
  • 北美地區在 2023 年以 37.98% 的收益佔有率佔據市場主導地位。該地區的收益成長得益於大量的研發活動和政府措施。此外，製藥公司和外包服務供應商的強大影響力也是推動市場成長的主要因素。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 藥物雜質合成與分離服務的變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望。
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 定價模式分析
  • 技術景觀
  • 醫藥雜質合成與分離服務市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章藥物雜質合成/分離服務市場：按服務分類的估計和趨勢分析

  • 細分儀表板
  • 全球醫藥雜質合成分離服務市場、服務波動分析
  • 2018-2030年全球藥物雜質合成與分離服務規模及趨勢分析（分服務）
  • 合成服務
  • 分離服務
  • 分析服務

第5章藥物雜質合成與分離服務市場：依雜質類型的估計和趨勢分析

  • 細分儀表板
  • 全球藥物雜質合成與分離服務市場、雜質類型波動分析
  • 2018-2030年全球藥物雜質合成與分離服務規模及趨勢分析（依雜質類型）
  • 無機雜質
  • 有機雜質
  • 殘留溶劑

第6章藥物雜質合成與分離服務市場：技術估算與趨勢分析

  • 細分儀表板
  • 全球藥物雜質合成與分離服務市場、技術變遷分析
  • 2018-2030年全球醫藥雜質合成與分離服務規模及趨勢分析（分技術）
  • 層析法
  • 光譜學
  • 結晶
  • 連字符技術
  • 其他

第7章藥物雜質合成與分離服務市場：依應用估算與趨勢分析

  • 細分儀表板
  • 全球藥物雜質合成與分離服務市場、應用變遷分析
  • 2018-2030年全球藥物雜質合成與分離服務規模及趨勢分析（依應用）
  • 商業製造
    • 2018-2030 年市場估計與預測
  • 藥物開發
    • 2018-2030 年市場估計與預測
  • 品管
    • 2018-2030 年市場估計與預測
  • 監理合規性
    • 2018-2030 年市場估計與預測

第8章藥物雜質合成和分離服務市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 全球藥物雜質合成與分離服務市場最終用途變化分析；
  • 2018-2030年全球藥物雜質合成和分離服務的規模和趨勢分析（按最終用途）
  • 生物技術和製藥公司
  • 受託研究機構（CRO）
  • 其他

第9章藥物雜質合成和分離服務市場：按服務、雜質類型、技術、應用和最終用途進行區域估計和趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第10章競爭格局

  • 公司分類
  • 2023 年企業市場分析
  • 公司簡介
    • Eurofins Scientific
    • Charles River Laboratories
    • Wuxi AppTec
    • SGS Societe Generale de Surveillance SA.
    • Intertek Group Plc
    • Almac Group
    • Cambrex Corporation
    • Pharmaron
    • Laboratory Corporation of America Holdings
    • Syngene International Limited
    • PCI Pharma Services
    • Catalent Inc
    • Symeres
    • Piramal Pharma Solutions
    • Frontage Labs
    • Veeda Clinical Research
Product Code: GVR-4-68040-435-5

Pharmaceutical Impurity Synthesis And Isolation Services Market Growth & Trends:

The global pharmaceutical impurity synthesis and isolation services market size is expected to reach USD 1.94 billion by 2030, growing at a CAGR of 8.03% during the forecast period, according to a new report by Grand View Research, Inc.

Pharmaceutical impurity testing, quantification, and analytical control strategies are important in optimizing safety, purity, and quality control for finished drug products and drug substances. Pharmaceutical impurities can arise from several sources and include reagents, starting materials and their contaminants, catalysts, intermediates, solvents, excipients and their contaminants, and degradation products.

The growing complexity of pharmaceutical formulations is also contributing to market growth. With the increasing development of biologics, complex generics, and novel drug delivery systems, the nature of impurities has become more diverse and challenging to identify. This complexity necessitates advanced analytical techniques and expert services for accurate impurity profiling. Companies seek specialized services to handle these requirements, driving demand for impurity synthesis and isolation services. Thus, the aforementioned factors contribute to market growth.

Moreover, continuous technological advancements in analytical techniques further driving the demand for impurity synthesis and isolation services. The development of more sophisticated methods, such as high-resolution mass spectrometry and advanced chromatographic techniques, enables more precise detection and characterization of impurities. Service providers that adopt and integrate these cutting-edge technologies would easily meet the growing needs of the pharmaceutical industry, further driving growth in the market.

Growing collaboration and outsourcing trends in the pharmaceutical industry play a significant role in the market dynamics. Pharmaceutical companies are increasingly outsourcing impurity synthesis and isolation to specialized service providers to focus on their core competencies and reduce operational costs. This outsourcing trend creates opportunities for service providers to expand their offerings and cater to global clients. Thus, the aforementioned factors are driving the growth of the market.

Pharmaceutical Impurity Synthesis And Isolation Services Market Report Highlights:

  • Based on service, the isolation service segment dominated the market with a share of 39.41% in 2023. Isolation of impurities is a fundamental aspect of ensuring the safety and efficacy of pharmaceutical products. Regulatory agencies require comprehensive impurity profiles, which necessitate effectively isolating these substances from drug formulations.
  • Based on impurity type, the inorganic impurities segment dominated the market in 2023. Technological advancements have played a significant role in dominating the segment of inorganic impurities. Innovations in analytical techniques, such as Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and Atomic Absorption Spectroscopy (AAS), have greatly enhanced the ability to detect and quantify inorganic impurities with high sensitivity and accuracy.
  • Based on technique, the chromatography segment accounted for the largest revenue share in 2023. Increasing complexity of pharmaceutical formulations is driving the demand for advanced chromatographic techniques. Modern drugs, including biologics, peptides, and complex generics, often involve intricate mixtures that require proper separation methods.
  • Based on application, the commercial manufacturing segment accounted for the largest revenue share in 2023. Growing global pharmaceutical market and expanding pharmaceutical production facilities worldwide are contributing to the segment's growth. As pharmaceutical companies increase their production capacities and enter new markets, the need for reliable impurity analysis services grows significantly.
  • Based on end use, the biotech and pharmaceutical companies segment accounted for the largest revenue share in 2023. Biotech and pharmaceutical companies' significant investment in research and development (R&D) is contributing to the segment's growth.
  • North America dominated the market with a revenue share of 37.98% in 2023. The regional revenue growth is owing to high R&D activities and government initiatives. Moreover, strong presence of pharmaceutical companies and outsourcing service providers is another major factor expected to propel market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Service
    • 1.2.2. Impurity Type
    • 1.2.3. Technique
    • 1.2.4. Application
    • 1.2.5. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pharmaceutical Impurity Synthesis and Isolation Services Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Stringent Regulatory Landscape
      • 3.2.1.2. Increasing Pharmaceutical R&D Spending
      • 3.2.1.3. Technological Advancement in Analytical Testing
      • 3.2.1.4. Growing Outsourcing Trend in the Market
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of Skilled workforce
      • 3.2.2.2. Contractual Obligation
  • 3.3. Pricing Model Analysis
  • 3.4. Technology Landscape
  • 3.5. Pharmaceutical Impurity Synthesis and Isolation Services Market Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis
    • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical Impurity Synthesis And Isolation Services Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Pharmaceutical Impurity Synthesis and Isolation Services Market; Service Movement Analysis
  • 4.3. Global Pharmaceutical Impurity Synthesis and Isolation Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 4.4. Synthesis Services
    • 4.4.1. Synthesis services market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Isolation Services
    • 4.5.1. Isolation services market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Analytical Services
    • 4.6.1. Analytical services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmaceutical Impurity Synthesis And Isolation Services Market: Impurity Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Pharmaceutical Impurity Synthesis and Isolation Services Market; Impurity Type Movement Analysis
  • 5.3. Global Pharmaceutical Impurity Synthesis and Isolation Services Size & Trend Analysis, by Impurity Type, 2018 to 2030 (USD Million)
  • 5.4. Inorganic Impurities
    • 5.4.1. Inorganic impurities market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Organic impurities
    • 5.5.1. Organic impurities market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Residual Solvents
    • 5.6.1. Residual solvents market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmaceutical Impurity Synthesis And Isolation Services Market: Technique Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Pharmaceutical Impurity Synthesis and Isolation Services Market; Technique Movement Analysis
  • 6.3. Global Pharmaceutical Impurity Synthesis and Isolation Services Size & Trend Analysis, by Technique, 2018 to 2030 (USD Million)
  • 6.4. Chromatography
    • 6.4.1. Chromatography market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. HPLC
      • 6.4.2.1. HPLC market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Gas Chromatography
      • 6.4.3.1. Gas chromatography market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Preparative Chromatography
      • 6.4.4.1. Preparative chromatography market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Others
      • 6.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Spectroscopy
    • 6.5.1. Spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Mass Spectroscopy
      • 6.5.2.1. Mass spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Nuclear Magnetic Resonance (NMR) Spectroscopy
      • 6.5.3.1. Nuclear Magnetic Resonance (NMR) spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Others
      • 6.5.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Crystallization
    • 6.6.1. Crystallization market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Hyphenated Techniques
    • 6.7.1. Hyphenated techniques market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Pharmaceutical Impurity Synthesis And Isolation Services Market: Application Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Pharmaceutical Impurity Synthesis and Isolation Services Market; Application Movement Analysis
  • 7.3. Global Pharmaceutical Impurity Synthesis and Isolation Services Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 7.4. Commercial Manufacturing
    • 7.4.1. Commercial manufacturing market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Drug Development
    • 7.5.1. Drug development market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Quality Control
    • 7.6.1. Quality control market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Regulatory Compliance
    • 7.7.1. Regulatory compliance market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Pharmaceutical Impurity Synthesis And Isolation Services Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Pharmaceutical Impurity Synthesis and Isolation Services Market; End Use Movement Analysis
  • 8.3. Global Pharmaceutical Impurity Synthesis and Isolation Services Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 8.4. Biotech & Pharmaceutical Companies
    • 8.4.1. Biotech & pharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Contract Research Organizations (CRO)
    • 8.5.1. Contract Research Organizations (CRO) market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Others
    • 8.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Pharmaceutical Impurity Synthesis And Isolation Services Market: Regional Estimates & Trend Analysis by Service, Impurity Type, Technique, Application, End Use

  • 9.1. Regional Market Share Analysis, 2023 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.4. North America
    • 9.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 9.4.2. U.S.
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Competitive scenario
      • 9.4.2.3. Regulatory framework
      • 9.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.3. Canada
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Competitive scenario
      • 9.4.3.3. Regulatory framework
      • 9.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.4. Mexico
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Competitive scenario
      • 9.4.4.3. Regulatory framework
      • 9.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5. Europe
    • 9.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 9.5.2. UK
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Competitive scenario
      • 9.5.2.3. Regulatory framework
      • 9.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.3. Germany
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Competitive scenario
      • 9.5.3.3. Regulatory framework
      • 9.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.4. France
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Competitive scenario
      • 9.5.4.3. Regulatory framework
      • 9.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.5. Italy
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. Competitive scenario
      • 9.5.5.3. Regulatory framework
      • 9.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.6. Spain
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Competitive scenario
      • 9.5.6.3. Regulatory framework
      • 9.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.7. Denmark
      • 9.5.7.1. Key country dynamics
      • 9.5.7.2. Competitive scenario
      • 9.5.7.3. Regulatory framework
      • 9.5.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.8. Sweden
      • 9.5.8.1. Key country dynamics
      • 9.5.8.2. Competitive scenario
      • 9.5.8.3. Regulatory framework
      • 9.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.9. Norway
      • 9.5.9.1. Key country dynamics
      • 9.5.9.2. Competitive scenario
      • 9.5.9.3. Regulatory framework
      • 9.5.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 9.6.2. Japan
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Competitive scenario
      • 9.6.2.3. Regulatory framework
      • 9.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.3. China
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Competitive scenario
      • 9.6.3.3. Regulatory framework
      • 9.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.4. India
      • 9.6.4.1. Key country dynamics
      • 9.6.4.2. Competitive scenario
      • 9.6.4.3. Regulatory framework
      • 9.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.5. Australia
      • 9.6.5.1. Key country dynamics
      • 9.6.5.2. Competitive scenario
      • 9.6.5.3. Regulatory framework
      • 9.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.6. South Korea
      • 9.6.6.1. Key country dynamics
      • 9.6.6.2. Competitive scenario
      • 9.6.6.3. Regulatory framework
      • 9.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.7. Thailand
      • 9.6.7.1. Key country dynamics
      • 9.6.7.2. Competitive scenario
      • 9.6.7.3. Regulatory framework
      • 9.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7. Latin America
    • 9.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 9.7.2. Brazil
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Competitive scenario
      • 9.7.2.3. Regulatory framework
      • 9.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.3. Argentina
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Competitive scenario
      • 9.7.3.3. Regulatory framework
      • 9.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8. MEA
    • 9.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 9.8.2. South Africa
      • 9.8.2.1. Key country dynamics
      • 9.8.2.2. Competitive scenario
      • 9.8.2.3. Regulatory framework
      • 9.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key country dynamics
      • 9.8.3.2. Competitive scenario
      • 9.8.3.3. Regulatory framework
      • 9.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.8.4. UAE
      • 9.8.4.1. Key country dynamics
      • 9.8.4.2. Competitive scenario
      • 9.8.4.3. Regulatory framework
      • 9.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key country dynamics
      • 9.8.5.2. Competitive scenario
      • 9.8.5.3. Regulatory framework
      • 9.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Company Market Position Analysis, 2023
  • 10.3. Company Profiles
    • 10.3.1. Eurofins Scientific
      • 10.3.1.1. Company overview
      • 10.3.1.2. Financial performance
      • 10.3.1.3. Service benchmarking
      • 10.3.1.4. Strategic initiatives
    • 10.3.2. Charles River Laboratories
      • 10.3.2.1. Company overview
      • 10.3.2.2. Financial performance
      • 10.3.2.3. Service benchmarking
      • 10.3.2.4. Strategic initiatives
    • 10.3.3. Wuxi AppTec
      • 10.3.3.1. Company overview
      • 10.3.3.2. Financial performance
      • 10.3.3.3. Service benchmarking
      • 10.3.3.4. Strategic initiatives
    • 10.3.4. SGS Societe Generale de Surveillance SA.
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Service benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Intertek Group Plc
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Service benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Almac Group
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Service benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. Cambrex Corporation
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Service benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. Pharmaron
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Service benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Laboratory Corporation of America Holdings
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Service benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. Syngene International Limited
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Service benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. PCI Pharma Services
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Service benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. Catalent Inc
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Service benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. Symeres
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Service benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Piramal Pharma Solutions
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Service benchmarking
      • 10.3.14.4. Strategic initiatives
    • 10.3.15. Frontage Labs
      • 10.3.15.1. Company overview
      • 10.3.15.2. Financial performance
      • 10.3.15.3. Service benchmarking
      • 10.3.15.4. Strategic initiatives
    • 10.3.16. Veeda Clinical Research
      • 10.3.16.1. Company overview
      • 10.3.16.2. Financial performance
      • 10.3.16.3. Service benchmarking
      • 10.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 4 Global Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 5 Global Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 6 Global Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 7 Global Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 8 Global Pharmaceutical Impurity Synthesis and Isolation Services, by Region, 2018 - 2030 (USD Million)
  • Table 9 North America Pharmaceutical Impurity Synthesis and Isolation Services, by Country, 2018 - 2030 (USD Million)
  • Table 10 North America Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 11 North America Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 12 North America Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 13 North America Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 14 North America Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 15 U.S. Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 16 U.S. Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 17 U.S. Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 18 U.S. Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 19 U.S. Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Canada Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 21 Canada Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 22 Canada Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 23 Canada Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 24 Canada Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Mexico Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 26 Mexico Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 27 Mexico Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 28 Mexico Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 29 Mexico Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 30 UK Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 31 UK Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 32 UK Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 33 UK Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 34 UK Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Germany Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 36 Germany Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 37 Germany Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 38 Germany Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 39 Germany Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 40 France Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 41 France Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 42 France Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 43 France Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 44 France Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Italy Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 46 Italy Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 47 Italy Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 48 Italy Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 49 Italy Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Spain Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 51 Spain Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 52 Spain Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 53 Spain Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 54 Spain Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 55 Sweden Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 56 Sweden Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 57 Sweden Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 58 Sweden Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 59 Sweden Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 60 Norway Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 61 Norway Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 62 Norway Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 63 Norway Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 64 Norway Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Denmark Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 66 Denmark Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 67 Denmark Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 68 Denmark Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 69 Denmark Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 70 India Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 71 India Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 72 India Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 73 India Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 74 India Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 75 China Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 76 China Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 77 China Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 78 China Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 79 China Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 80 Japan Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 81 Japan Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 82 Japan Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 83 Japan Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 84 Japan Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 85 India Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 86 India Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 87 India Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 88 India Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 89 India Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 90 Australia Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 91 Australia Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 92 Australia Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 93 Australia Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 94 Australia Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 95 Thailand Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 96 Thailand Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 97 Thailand Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 98 Thailand Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 99 Thailand Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 100 South Korea Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 101 South Korea Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 102 South Korea Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 103 South Korea Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 104 South Korea Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 105 Brazil Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 106 Brazil Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 107 Brazil Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 108 Brazil Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 109 Brazil Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 110 Argentina Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 111 Argentina Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 112 Argentina Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 113 Argentina Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 114 Argentina Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 117 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 118 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 119 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 120 UAE Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 121 UAE Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 122 UAE Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 123 UAE Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 124 UAE Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)
  • Table 125 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services, by Service, 2018 - 2030 (USD Million)
  • Table 126 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services, by Impurity Type, 2018 - 2030 (USD Million)
  • Table 127 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services, by Technique, 2018 - 2030 (USD Million)
  • Table 128 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services, by Application, 2018 - 2030 (USD Million)
  • Table 129 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Pharmaceutical Impurity Synthesis and Isolation Services, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Service, 2018 - 2030 (USD Million)
  • Fig. 13 Global Pharmaceutical Impurity Synthesis and Isolation Synthesis Services, for Synthesis Services, 2018 - 2030 (USD Million)
  • Fig. 14 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Isolation Services, 2018 - 2030 (USD Million)
  • Fig. 15 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Analytical Services, 2018 - 2030 (USD Million)
  • Fig. 16 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Organic Impurities, 2018 - 2030 (USD Million)
  • Fig. 17 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Inorganic Impurities, 2018 - 2030 (USD Million)
  • Fig. 18 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Residual Solvents, 2018 - 2030 (USD Million)
  • Fig. 19 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Chromatography, 2018 - 2030 (USD Million)
  • Fig. 20 Global Chromatography Pharmaceutical Impurity Synthesis and Isolation Services, for HPLC, 2018 - 2030 (USD Million)
  • Fig. 21 Global Chromatography Pharmaceutical Impurity Synthesis and Isolation Services, for Gas Chromatography, 2018 - 2030 (USD Million)
  • Fig. 22 Global Chromatography Pharmaceutical Impurity Synthesis and Isolation Services, for Preparative Chromatography, 2018 - 2030 (USD Million)
  • Fig. 23 Global Chromatography Pharmaceutical Impurity Synthesis and Isolation Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 24 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Spectroscopy, 2018 - 2030 (USD Million)
  • Fig. 25 Global Spectroscopy Pharmaceutical Impurity Synthesis and Isolation Services, for Mass Spectroscopy, 2018 - 2030 (USD Million)
  • Fig. 26 Global Spectroscopy Pharmaceutical Impurity Synthesis and Isolation Services, for Nuclear Magnetic Resonance (NMR) Spectroscopy, 2018 - 2030 (USD Million)
  • Fig. 27 Global Spectroscopy Pharmaceutical Impurity Synthesis and Isolation Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 28 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Crystallization, 2018 - 2030 (USD Million)
  • Fig. 29 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Hyphenated Techniques, 2018 - 2030 (USD Million)
  • Fig. 30 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 31 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Drug Development, 2018 - 2030 (USD Million)
  • Fig. 32 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Commercial Manufacturing, 2018 - 2030 (USD Million)
  • Fig. 33 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Quality Control, 2018 - 2030 (USD Million)
  • Fig. 34 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Regulatory Compliance, 2018 - 2030 (USD Million)
  • Fig. 35 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Biotech & Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 36 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Contract Research Organizations (CRO), 2018 - 2030 (USD Million)
  • Fig. 37 Global Pharmaceutical Impurity Synthesis and Isolation Services, for Others, 2018 - 2030 (USD Million)
  • Fig. 38 Regional Outlook, 2023 & 2030
  • Fig. 39 North America Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 US Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Mexico Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Germany Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Italy Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Spain Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Denmark Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Sweden Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Norway Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Japan Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 China Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 India Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Australia Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Korea Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Latin America Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Brazil Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Argentina Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Middle East and Africa Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 South Africa Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Saudi Arabia Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 UAE Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Kuwait Pharmaceutical Impurity Synthesis and Isolation Services Market Estimates and Forecasts, 2018 - 2030 (USD Million)